Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

22
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
22
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

14
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
14
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

20
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
20
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

24
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
24
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

25
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
25
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visualizing Muscle Sialic Acid Expression in the GNED207VTgGne-/- Cmah-/- Model of GNE Myopathy: A Comparison of Dietary and Gene Therapy Approaches.

Journal of neuromuscular diseases·2021
Same author

FKRP mutations cause congenital muscular dystrophy 1C and limb-girdle muscular dystrophy 2I in Asian patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2021
Same author

A recurrent homozygous ACTN2 variant associated with core myopathy.

Acta neuropathologica·2021
Same author

Neuropathy/intranuclear inclusion bodies in oculopharyngodistal myopathy: A case report.

eNeurologicalSci·2021
Same author

Myoclonic Epilepsy with Ragged-red Fibers with Intranuclear Inclusions.

Internal medicine (Tokyo, Japan)·2021
Same author

A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke.

Nature communications·2021

Related Experiment Video

Updated: Sep 2, 2025

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.7K

Update on dermatomyositis.

Jantima Tanboon1,2, Ichizo Nishino2,3,4

  • 1Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Current Opinion in Neurology
|August 9, 2022
PubMed
Summary

New dermatomyositis classifications incorporate specific antibodies (DMSA) and interferon pathways. These advancements aid in disease monitoring and personalized treatment strategies for better patient outcomes.

More Related Videos

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.0K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

201

Related Experiment Videos

Last Updated: Sep 2, 2025

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

19.7K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.0K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

201

Area of Science:

  • Rheumatology and Immunology
  • Neuromuscular Disorders
  • Dermatology

Background:

  • The 2018 European Neuromuscular Centre classification for dermatomyositis requires updates.
  • New clinicopathological features linked to dermatomyositis-specific antibodies (DMSA) are not fully integrated.

Purpose of the Study:

  • To review current knowledge on dermatomyositis.
  • To discuss the impact of new DMSA discoveries on classification and treatment.

Main Methods:

  • Literature review and commentary on recent findings in dermatomyositis research.
  • Analysis of clinicopathological features associated with specific antibodies.

Main Results:

  • DMSA identification (e.g., anti-Mi-2, anti-MDA5, anti-NXP-2) reveals distinct features and prognostic subgroups.
  • Interferon (IFN) pathway activation is prominent in dermatomyositis.
  • JAK-STAT inhibitors show promise for refractory and new-onset dermatomyositis.

Conclusions:

  • DMSA, IFN pathway activation, and biomarkers are crucial for future dermatomyositis classification.
  • These factors will guide disease monitoring and treatment decisions.
  • Further research into serum biomarkers for IFN pathway monitoring is warranted.